Emcure to push Sanofi's oncology range in India

Emcure Pharmaceuticals will market Sanofi's oncology portfolio in India as part of efforts by both partners to leverage the benefits of providing a comprehensive and complementary range of products in the segment.

This is Sanofi's third alliance with Emcure, after a similar deal for Sanofi-Pasteur’s rabies vaccine Verorab and a non-exclusive distribution...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Quick Listen: Scrip’s Five Must-Know Things

16 Jun 2025

• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

11 Jun 2025

• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

11 Jun 2025

• By Sushmita Panda

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.